Development and characterization of ultra-stable insulin analogs for novel therapeutic use

糖尿病是一个重大的公共卫生负担。在美国和全世界， 已经观察到1型糖尿病（T1 DM）和糖尿病性糖尿病（DM）的患病率逐渐增加， 2型糖尿病（T2 DM）。本申请的重点是开发药物稳定的胰岛素 类似物，其可应用于新型药物递送系统。申请人是MSTP学生谁寻求 培养生物化学对未来的职业生涯，整合临床护理与新的发展， 治疗和设备。 临床胰岛素治疗方案必须通过谨慎的剂量协调来补偿调节分泌的损失 患者的食物摄入量、活动水平和连续葡萄糖监测结果。坚持这种 治疗方案需要每天多次自我注射。这样的递送方法不仅引起患者的不适， 但是，它们也难以在时间和准确的剂量施用方面维持。的 通过开发替代机制，可提高当前治疗方案的安全性和有效性 用于胰岛素给药。胰岛素的本质是一种肽激素，易受化学物质和 温度诱导的降解是其在新型递送系统中实施的主要障碍。 本申请描述了本发明的两种先前表征的稳定化修饰的组合。 胰岛素激素，将用于产生热稳定的胰岛素类似物，可以制成PLGA- 聚合物基质并保持其生物活性。这些注入胰岛素的聚合物将被开发成 微针植入物将作为基础胰岛素输送系统。这些植入物将减少 自我注射的频率，同时提供安全，一致和连续剂量的胰岛素。 由于拟议研究的跨学科性质，实验室导师由小学论文 顾问（M。医学博士韦斯，博士学位;生物化学，生物医学工程和医学教授）将 由临床大师（糖尿病学家F. Ismail-Beigi，医学教授），X射线 晶体学专家（V. Yee;生物化学副教授），材料科学家，专门从事 大分子科学（J. Pokorski;大分子科学教授）。此外，咨询 顾问D.安德森和R.兰格是马萨诸塞州理工学院的蛋白质工程师， 为项目的发展提供更多的指导。

Diabetes mellitus poses a major public-health burden. Both in the United States and throughout the world, progressive increases have been observed in the prevalence of both Type 1 diabetes mellitus (T1DM) and Type 2 diabetes (T2DM). This application focuses on the development of thermodynamically stable insulin analogs that may be applied to novel drug-delivery systems. The applicant is an MSTP student who seeks training in biochemistry toward a future career that integrates clinical care with the development of novel therapeutics and devices. Clinical insulin regimens must compensate for the loss of regulated secretion by careful dosing coordinated with the patient's food intake, level of activity, and results of serial glucose monitoring. Adherence to such regimens requires self-injections several times a day. Such delivery methods not only cause discomfort for the patient, but they are also difficult to maintain in terms of timing and accurate administration of doses. The safety and efficacy of current regimens may be enhanced through the development of alternative mechanisms for insulin administration. Insulin's nature as a peptide hormone that is susceptible to chemical and temperature-induced degradation is a major barrier for its implementation in novel delivery systems. This application describes the combination of two previously characterized stabilizing modifications of the insulin hormone that will be used to create heat-stable insulin analogs that can be fabricated into PLGA- polymeric matrices and retain their biological activity. These insulin-infused polymers will be developed into microneedle implants that will serve as basal insulin delivery systems. These implants will reduce the frequency of self-injection while delivering safe, consistent, and continuous doses of insulin. Because of the interdisciplinary nature of the proposed studies, laboratory mentorship by the primary Thesis Advisor (M. Weiss, M.D., Ph.D.; Professor of Biochemistry, Biomedical Engineering & Medicine) will be complemented by a master clinician (diabetologist F. Ismail-Beigi, Professor of Medicine), an X-ray crystallography expert (V. Yee; Associate Professor of Biochemistry), and materials-scientist specializing in macromolecular sciences (J. Pokorski; Professor of Macromolecular Sciences). Additionally, consulting advisors D. Anderson and R. Langer, protein engineers at the Massachusetts Institute of Technology, will provide additional guidance on the development of the project.